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Abstract
Objective: We aimed to re-examine mortality risk estimates for metabolically healthy obesity by using a ‘stable’ 
healthy non-obese referent group.
Design: Prospective cohort study.
Methods: Participants were 5427 men and women (aged 65.9 ± 9.4 years, 45.9% men) from the English Longitudinal 
Study of Ageing. Obesity was defined as body mass index ≥30 kg/m2 (vs non-obese as below this threshold). Based on 
blood pressure, HDL cholesterol, triglycerides, glycated hemoglobin and C-reactive protein, participants were classified 
as ‘healthy’ (0 or 1 metabolic abnormality) or ‘unhealthy’ (≥2 metabolic abnormalities).
Results: Totally, 671 deaths were observed over an average follow-up of 8 years. When defining the referent group 
based on 1 clinical assessment, the unhealthy non-obese (hazard ratio (HR) = 1.22; 95% CI: 1.01, 1.45) and unhealthy 
obese (HR = 1.29; CI: 1.05, 1.60) were at greater risk of all-cause mortality compared to the healthy non-obese, yet 
no excess risk was seen in the healthy obese (HR = 1.14; CI: 0.83, 1.52). When we re-defined the referent group based 
on 2 clinical assessments, effect estimates were accentuated and healthy obesity was at increased risk of mortality 
(HR = 2.67; CI: 1.64, 4.34).
Conclusion: An unstable healthy referent group may make ‘healthy obesity’ appear less harmful by obscuring the 
benefits of remaining never obese without metabolic dysfunction.
Introduction
Termed ‘metabolically healthy obesity’, population-based 
studies have identified an obesity phenotype that is not 
accompanied by a clustering of adiposity-associated 
cardio-metabolic risk factors (1). Although tendencies 
for metabolic decline and for developing type 2 diabetes 
are becoming clear (1), associations of healthy obesity 
with outcomes related to cardiovascular disease and 
mortality are less consistent (2, 3). One explanation for 
these inconsistencies may be differences in the duration 
of follow-up used across studies, with those using shorter 
follow-up times tending to find no association between 
healthy obesity and outcomes (4, 5). Some studies have 
considered instability of healthy obesity itself as another 
potential explanation (6, 7, 8); yet little-to-no attention 
has focused on the importance of the group to which 
healthy obesity is being compared, usually defined as 
some form of ‘healthy non-obese’.
Studies that examine the risks of healthy obesity tend 
to rely on one-off measures of body mass index (BMI) 
and biomarkers of metabolic health. As a consequence, 
estimates of excess disease risk among healthy obese vs 
healthy non-obese adults may be obscured in at least two 
ways; one, by failing to distinguish those obese individuals 
who have been obese for many years from those who have 
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only recently gained enough weight to become obese; 
and two, by failing to distinguish referent non-obese 
individuals who have had a BMI below the obese range for 
many years from those who only recently became obese 
or who used to be obese but had lost weight. These same 
obscurities would apply to markers of metabolic health, 
although these are known to track closely with changes 
in BMI, even within the strictly normal-weight range (9).
This study aimed to improve risk estimates for 
mortality among healthy obese adults by examining 
associations using a stable healthy non-obese referent 
group defined from repeat biomedical assessments.
Subjects and methods
Study sample and procedures
The English Longitudinal Study of Ageing (ELSA) is 
an ongoing cohort study that contains a nationally 
representative sample of free-living men and women born 
on or before February 29, 1952 (10). Data collected in 2004–
2005 were used as the baseline for the present analysis 
as this was the first occasion; clinical data were measured 
objectively by a nurse. An identical clinical assessment was 
repeated 4 years later (2008–2009). Individual participant 
data were linked with death records from National Health 
Service registries for all consenting respondents (96.5% of 
the sample) up to February 2012. Participants gave full 
informed written consent to participate in the study, and 
ethical approval was obtained from the London Multi-
Centre Research Ethics Committee.
Clinical measurements
Nurses collected anthropometric data (weight, height), 
blood pressure (BP) and non-fasting blood samples using 
standard protocols. Body weight was measured without 
shoes and in light clothing using Tanita electronic scales, 
and height was measured using a stadiometer with the 
Frankfort plane in the horizontal position. BMI was 
calculated as weight (kilograms)/height (meters) squared. 
Systolic and diastolic BP was measured with an Omron 
HEM-907 blood pressure monitor three times in the 
sitting position after 5-min rest between each reading. 
The initial reading was discarded, and an average of the 
second and third BP recordings was used for the present 
analyses. Blood samples were analyzed for high-sensitivity 
C-reactive protein (CRP), high-density lipoprotein (HDL) 
cholesterol, triglycerides and glycated hemoglobin 
(HbA1c). Detailed information on the technicalities of 
the blood analysis, the internal quality control and the 
external quality assessment for the laboratory have been 
described elsewhere (11). Additional data were collected 
on physician diagnosed conditions (hypertension, 
diabetes) and medication use.
Covariates at baseline
Age and sex were recorded in 2004–2005. Ethnicity was 
not considered as the sample was ethnically homogeneous 
(93.9% white-British). Health behaviors included cigarette 
smoking (current, previous or non-smoker), the frequency 
of participation in light, moderate and vigorous physical 
activities (more than once per week, once per week, one to 
three times per month, hardly ever), any reported chronic 
illness and depressive symptoms (a score of 3 or higher 
out of 8 on the 8-item Centre of Epidemiological Studies 
Depression scale (12)). Wealth was used as a measure of 
socioeconomic status, as this has been shown to best 
capture the material resources available to older adults 
(13). Wealth was calculated as net of debt and included 
the total value of the participant’s home (excluding 
mortgage), financial assets such as savings, business assets 
and physical wealth such as artwork or jewelry.
Statistical analyses
We used conventional criteria to define obesity (BMI 
≥30 kg/m2). Underweight participants (BMI <18.5 kg/m2) 
were excluded to prevent possible reverse causation 
(as underweight is often a marker of serious illness in 
older adults). A healthy metabolic status was based on 
independently proposed criteria (14), and according 
to availability of data, defined as having less than 2 
of the following 5 metabolic risk factors: high BP (BP 
≥130/85 mmHg, or hypertension diagnosis or use of anti-
hypertensive medication), impaired glycemic control 
(HbA1c >6.0% (42.1 mmol/mol) or doctor’s diagnosed 
diabetes), systemic inflammation (CRP ≥ 3 mg/L), low 
HDL cholesterol (<1.03 mmol/L in men and <1.30 mmol/L 
in women) and high triacylglycerol (≥1.7 mmol/L). 
Participants were then categorized into 1 of 4 groups: 
‘healthy non-obese’, ‘unhealthy non-obese’, ‘healthy 
obese’ and ‘unhealthy obese’. We used Cox proportional 
hazards regression models to examine associations 
between metabolic-BMI group and mortality, with healthy 
non-obese based on the 2004–2005 assessment. Age at 
death was recorded, and years were the time scale for the 
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follow-up. For consenting participants with no record of 
an event, the data were censored at February 2012. The 
proportional hazards assumption was examined by using 
plots of the Nelson-Aalen cumulative hazard estimates. 
We estimated models that were initially adjusted for age 
and sex. The final models were additionally adjusted for 
physical activity, smoking, depressive symptoms (CES-D 
>3) and chronic illness, wealth. These covariates were 
selected a priori based on previous literature (4, 6, 8). 
These analyses were repeated with the healthy non-obese 
referent group refined to include only participants who 
met criteria for a healthy status and were non-obese in 
both 2004–2005 and 2008–2009. All other participants 
remained assigned to their baseline categories, and those 
from the original referent category that transitioned 
into unhealthy/obese groups (n = 515) or did not provide 
data at follow-up (n = 994) were removed. Deaths in 
the first 4  years of follow-up were removed in order to 
retain consistency with the new referent category. All 
models were repeated in sensitivity analyses using a 
more stringent definition of metabolic health, defined as 
having 0 of 5 risk factors. A two-sided P value of 0.05 was 
used to indicate statistical significance. All analyses were 
conducted using SPSS version 22 (SPSS).
Results
A total of 8688 participants (82% of participants at the 
first point of contact in 2002–2003) attended the clinical 
assessment in 2004–2005. The present study reports only 
on those that consented and were eligible and able to 
give blood (n = 5903); this excluded men and women with 
clotting and bleeding disorders, or taking anti-coagulant 
medication. After excluding 79 participants that did 
not provide consent to linkage of mortality records, 
and a further 397 because of missing data, the final 
analytic sample comprised 5427 men and women (aged 
65.9 ± 9.4 years, 45.9% men).
Descriptive characteristics of the sample are displayed 
in Table 1. Around 46.0% of the sample were characterized 
as ‘healthy non-obese’, 25.2% as ‘unhealthy non-obese’, 
9.5% as ‘healthy obese’ and 19.3% as ‘unhealthy obese’. 
The healthy non-obese were generally wealthier than 
other participants and displayed better health behavior 
including higher physical activity levels, fewer depressive 
symptoms and chronic illnesses.
A total of 671 deaths were observed over an average 
follow-up of 8  years. In covariate-adjusted models that 
defined the healthy non-obese referent group based 
on 2004–2005 only (Table  2), the unhealthy non-
obese (hazard ratio (HR) = 1.22; 95% CI: 1.01, 1.45) 
and unhealthy obese (HR = 1.29; CI: 1.05, 1.60) were at 
greater risk of mortality, although no excess risk was 
observed in the healthy obese (HR = 1.14; CI: 0.83, 1.52). 
A similar pattern emerged for death from cardiovascular 
diseases (CVD) although significant excess risk remained 
only among the unhealthy obese in the final model. 
Medication (including anti-hypertensive, lipid lowering 
and diabetes medications) was used in 35.9% of the cohort 
at baseline. The results were not substantially different 
after controlling for medication use (Supplementary 
Table 1, see section on supplementary data given at the 
end of this article).
During 4 years of follow-up, 65.8% of healthy non-
obese participants remained stable in this category 
(Supplementary Table  2). In covariate-adjusted models 
Table 1 Baseline characteristics of the sample (n = 5427).
 
 
 
 
Metabolically 
healthy 
non-obese 
(n = 2503)
Metabolically 
unhealthy 
non-obese 
(n = 1364)
 
Metabolically 
healthy obese 
(n = 514)
 
Metabolically 
unhealthy obese 
(n = 1046)
Age (years) 65.5 ± 9.5 67.7 ± 9.6 64.3 ± 8.8 65.6 ± 9.0
Men (%) 44.6 52.5 43.8 41.4
Depressive symptoms (% CES-D >3) 11.6 14.3 13.2 16.6
Longstanding illness (%) 44.2 58.3 46.9 65.0
Current smokers (%) 14.1 20.7 9.9 16.3
Vigorous physical activity (% at least once/week) 37.0 26.4 28.4 20.7
Lowest wealth quintile (%) 10.6 15.2 13.4 21.6
Body mass index (kg/m2) 25.1 ± 2.7 26.4 ± 2.4 32.8 ± 2.9 34.1 ± 3.9
HDL cholesterol (mmol/L) 1.67 ± 0.37 1.37 ± 0.36 1.54 ± 0.30 1.34 ± 0.32
Triglycerides (mmol/L) 1.37 ± 0.71 2.28 ± 1.06 1.54 ± 0.73 2.42 ± 1.74
HbA1c (%) 5.39 ± 0.38 5.77 ± 0.86 5.47 ± 0.41 5.95 ± 0.95
C-reactive protein (mg/L) 1.93 ± 3.41 5.11 ± 7.73 2.90 ± 4.48 6.26 ± 7.59
Systolic BP (mmHg) 130.5 ± 17.1 139.5 ± 18.7 135.8 ± 15.8 140.5 ± 18.3
Diastolic BP (mmHg) 73.2 ± 9.8 76.2 ± 11.9 75.9 ± 8.6 79.1 ± 11.6
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that re-defined the healthy non-obese referent group 
based on data from both 2004–2005 and 2008–2009, 
effect estimates for mortality were accentuated in the 
unhealthy non-obese and obese groups, and the healthy 
obese were also at increased risk (HR = 2.67; CI: 1.64, 
4.34) (Table 3).
In sensitivity analyses, we used the more stringent 
definition of metabolic health (based on 0 of 5 risk 
factors) although results remained largely unchanged 
(Supplementary Table  3). Our original criterion for 
metabolic health was based on the clinically valid 
CRP threshold of 3 mg/L (15). We also re-defined 
metabolic health using the 90th percentile for CRP 
(8.2 mg/L in our sample), as used by others (14), 
although the results were not substantially changed 
(Supplementary Table 4).
Discussion
The aim of this study was to examine associations 
between metabolically healthy obesity phenotype and 
mortality. Unlike previous studies we defined the healthy 
non-obese referent category from repeated biomedical 
assessments in order to ensure that risk among healthy 
obese adults was compared with that of adults who 
remained never obese without metabolic risk factors over 
an extended period of time. Using this refined referent 
category, our results suggest that excess risk of mortality 
among unhealthy non-obese and unhealthy obese groups 
is greater than previously thought, and that risk is indeed 
elevated among the healthy obese.
Previous studies (2, 3, 4, 5) had defined the referent 
category (‘healthy non-obese’) based on clinical 
Table 2 Cox proportional hazards regression for associations of obesity, metabolic health and mortality, with referent healthy 
non-obese group defined by status in 2004–2005 only (n = 5427).
  HR (95% CI)
Baseline metabolic 
health/obesity status Number of deaths/total n Model 1 Model 2
All deaths    
Healthy non-obese 262/2503 1.00 (ref) 1.00 (ref)
Unhealthy non-obese 215/1364 1.35 (1.12, 1.61) 1.22 (1.01, 1.45)
Healthy obese 52/514 1.20 (0.89, 1.62) 1.14 (0.83, 1.52)
Unhealthy obese 142/1046 1.51 (1.23, 1.86) 1.29 (1.05, 1.60)
CVD deaths   
Healthy non-obese 62/2503 1.00 (ref) 1.00 (ref)
Unhealthy non-obese 54/1364 1.43 (1.00, 2.06) 1.29 (0.89, 1.87)
Healthy obese 9/514 0.98 (0.49, 1.97) 0.92 (0.45, 1.86)
Unhealthy obese 38/1046 1.91 (1.27, 2.88) 1.57 (1.03, 2.40)
Model 1 adjusted for age and sex. Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms, chronic illness.
Table 3 Cox proportional hazards regression for associations of obesity, metabolic health and mortality, with referent healthy 
non-obese group based on status in both 2004–2005 and 2008–2009 (n = 3868).
  HR (95% CI)
Baseline metabolic health/
obesity status Number of deaths/total n Model 1 Model 2
All deaths    
Stable healthy non-obese† 27/992 1.00 (ref) 1.00 (ref)
Unhealthy non-obese 186/1335 3.52 (2.34, 5.28) 2.99 (1.98, 4.52)
Healthy obese 43/505 2.98 (1.84, 4.83) 2.67 (1.64, 4.34)
Unhealthy obese 132/1036 4.20 (2.78, 6.36) 3.50 (2.28, 5.35)
CVD deaths   
Stable healthy non-obese† 5/992 1.00 (ref) 1.00 (ref)
Unhealthy non-obese 47/1335 4.15 (1.64, 10.49) 3.64 (1.42, 9.33)
Healthy obese 5/505 1.79 (0.52, 6.19) 1.55 (0.44, 5.42)
Unhealthy obese 35/1036 5.78 (2.26, 14.78) 4.67 (1.78, 12.22)
Model 1 adjusted for age and sex. Model 2 adjusted for age, sex, wealth, physical activity, smoking, depressive symptoms and chronic illness.
†Reference group contains participants that remained metabolically healthy non-obese over four-year follow-up. Participants from referent category 
that transitioned into unhealthy groups (n = 515) or did not provide data at follow-up (n = 994) were removed. Deaths from first 4 years of follow-up 
were removed in order to retain consistency with referent category.
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assessments made at a single point in time, thus potentially 
making ‘healthy obesity’ appear less harmful by making 
comparisons with a group that is heterogeneous with 
respect to obesity exposure. Indeed, an unstable referent 
category may create bias in several ways, such as through 
containing individuals who were recently obese but had 
lost weight due to the onset of disease. This issue is still 
possible in the groups as defined in our study, for example, 
if adults with very high BMI lost weight in response to 
disease yet still fell within the obese range of BMI. The 
number of individuals with very high BMI, however, was 
small in our sample (7.5% of obese above BMI 40 kg/m2); 
most were just above the obesity threshold of 30 kg/m2 
(72.5% of the obese being between 30 and 35 kg/m2). 
Nevertheless, the older age of participants in the present 
study remains a limitation, given that associations 
between BMI and mortality risk are more prone to reverse 
causation by way of subclinical disease-induced weight 
loss than are such associations when examined among 
younger adults (16).
The few studies that have made use of multiple 
observations of BMI over the life course to study disease 
outcomes suggest that each additional observation 
enhances predictive value, with future morbidity being 
a positive function of the duration of obesity (17, 18, 
19, 20, 21). This has been recently applied within the 
‘healthy obesity’ paradigm to demonstrate that greater 
duration of obesity was associated with higher likelihood 
of developing the metabolic syndrome (22).
This study has its limitations. We were only able to 
utilize biomedical data from two visits as weight histories 
prior to baseline were not available. Given a lack of 
consensus for the definition of metabolically healthy 
obesity, we defined metabolic health using an adaptation 
of previous criteria (14) according to availability of data. 
The decision to use a categorization of 0 or 1 metabolic 
risk factor to define a metabolically healthy status was 
to allow for consistency with previous work [14] and 
for clinical relevance. Sensitivity analyses using a more 
stringent definition based on zero metabolic risk factors 
to define metabolic health produced similar results, yet 
were necessarily based on smaller numbers of participants 
given that most ‘healthy’ obese adults present with 1 
risk factor.
In conclusion, using repeat biomedical assessments in 
order to define a referent group that remained never obese 
without metabolic risk factors for an extended period 
of time, our results suggest that the risk of mortality is 
far greater among unhealthy non-obese and unhealthy 
obese adults than previously thought, and is indeed 
elevated among the healthy obese. Previous studies may 
have underestimated the detrimental effects of ‘healthy 
obesity’ by obscuring the benefits of remaining never 
obese without metabolic risk factors.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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